Extensive-stage Small-cell Lung Cancer Clinical Trials in Shanghai, Shanghai Municipality
5 recruitingShanghai, Shanghai Municipality, China
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled183 locationsNCT06646276
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled158 locationsNCT07005128
Recruiting
Phase 1
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Extensive-stage Small-cell Lung Cancer
Amgen220 enrolled31 locationsNCT06598306
Recruiting
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.66 enrolled1 locationNCT06437509
Recruiting
Phase 2
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
Extensive-stage Small-cell Lung Cancer
Sichuan University61 enrolled8 locationsNCT05765825